more_reports

DarioHealth (DRIO) Expands Reach via Beluga Health Deal

  ()
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market

  ()
AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announces a partnership that it says will give it access to a network spanning all 50 states. Find out why analysts like the direction the company is taking.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1

  ()
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next

  ()
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application.
Tags: Biotechnology / Pharmaceuticals

uniQure Epilepsy Gene Therapy Data Draws Investor Focus

  ()
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.
Tags: Biotechnology / Pharmaceuticals

Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating

  ()
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction.
Tags: Biotechnology / Pharmaceuticals

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach

Research Report
  ()
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts.
Tags: Biotechnology / Pharmaceuticals

DarioHealth: Chronic Care Platform Drives Value

  ()
DarioHealth targets the booming digital health market with a multi-condition platform backed by 27 ADA studies. See pipeline growth, analyst targets, and key catalysts for investors.
Tags: Healthcare ServicesArtificial IntelligenceTechnologyMedical Devices

Grey Matters Health Inc. Advances US Alzheimer's Clinics

  ()
Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Four New ADA Studies Reveal Clinical Wins in Weight, Blood Sugar, and Healthcare Utilization

  ()
DarioHealth Corp. (DRIO:NASDAQ) presented four studies at the ADA Scientific Sessions reporting weight loss of up to 14.3%, fewer hospitalizations, and improved glycemic outcomes among high-risk cardiometabolic users of its digital health platform.
Tags: Healthcare ServicesArtificial IntelligenceTechnologyMedical Devices

Alzheimer's Imaging Push Gains Fresh Funding as U.S. Clinic Plans Move Forward

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed an expanded US$1.25 million private placement and said proceeds will support its Alzheimer's disease program and planned first U.S. brain-specific neuroimaging clinic.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand

  ()
Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.
Tags: Biotechnology / Pharmaceuticals

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth

  ()
Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.
Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program

  ()
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral.
Tags: Biotechnology / Pharmaceuticals

Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data

  ()
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026.
Tags: Biotechnology / Pharmaceuticals

Sernova Biotherapeutics Advances Toward Diabetes Solutions with FDA Orphan Drug Designation and Strengthened Capital Base

  ()
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.
Tags: Regenerative MedicineMedical DevicesLife Sciences Tools & Diagnostics

Expert Investing Ideas

NATG goes live on Kraken in

20
Days
:
21
Hours
:
46
Minutes
:
43
Seconds

July 8, 2026 · 10:00 a.m. EST

Learn More
Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biotech Secures Major FDA Orphan Drug Designation for Diabetes Treatment

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announces it has been granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy.
Tags: Regenerative MedicineMedical DevicesLife Sciences Tools & Diagnostics

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape

  ()
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA

  ()
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock.
Tags: Biotechnology / Pharmaceuticals

Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition

  ()
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors.
Tags: Biotechnology / Pharmaceuticals

A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience

  ()
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset.
Tags: Biotechnology / Pharmaceuticals